Where to Give Semaglutide Shot: The Complete Injection Site Guide for Optimal Absorption and Minimal Pain

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Semaglutide can be injected subcutaneously in three FDA-approved sites: abdomen (excluding 2 inches around navel), front or side of thighs, and back of upper arms
• Absorption rates vary by site: abdomen absorbs fastest (3-4 days to peak), thigh slowest (4-5 days), upper arm intermediate (3.5-4.5 days)
• Rotating injection sites within and between zones prevents lipohypertrophy, a thickening of fat tissue that reduces medication absorption by up to 25%
• The 2-inch rule matters: staying 2 inches away from previous injection sites, scars, moles, and the navel prevents tissue damage and maintains consistent absorption

Direct answer (40-60 words)

Semaglutide should be injected subcutaneously (into the fatty tissue layer) in one of three FDA-approved sites: the abdomen (at least 2 inches from the navel), the front or outer thigh, or the back of the upper arm. Rotate sites weekly to prevent tissue changes that reduce absorption. The abdomen typically provides the most consistent absorption and causes the least injection discomfort.

Table of contents

1. The three approved injection sites and why they matter
2. Absorption differences between sites: the pharmacokinetic data
3. The 2-inch rule and why spacing prevents lipohypertrophy
4. Site rotation patterns that work: the quadrant system
5. What most articles get wrong about upper arm injections
6. The abdomen advantage: why it's the first-choice site
7. Thigh injections: technique for patients who can't use abdomen
8. Pain reduction strategies by injection site
9. When injection site reactions mean something more serious
10. The lipohypertrophy problem: recognition and recovery
11. Special considerations: pregnancy, surgical scars, tattoos
12. FormBlends injection site decision tree
13. FAQ
14. Sources
15. Footer disclaimers

The three approved injection sites and why they matter

The FDA-approved prescribing information for semaglutide (both brand-name Ozempic and Wegovy, and compounded formulations) specifies three injection zones:

1. Abdomen: anywhere on the front of the belly, excluding a 2-inch radius around the navel
2. Thigh: front or outer (lateral) portion of the thigh, midway between hip and knee
3. Upper arm: back (posterior) surface of the upper arm, in the area between shoulder and elbow

These sites were chosen because they have adequate subcutaneous fat tissue in most adults, are accessible for self-injection, and provide predictable absorption. The subcutaneous layer in these zones is typically 5 to 15 millimeters thick, which is the target depth for the medication.

Semaglutide must go into subcutaneous fat, not muscle. Intramuscular injection causes faster, more erratic absorption and increases the risk of hypoglycemia in diabetic patients. The approved sites minimize the risk of accidentally hitting muscle.

Absorption differences between sites: the pharmacokinetic data

A 2018 pharmacokinetic study published in Diabetes, Obesity and Metabolism (Kapitza et al.) measured semaglutide absorption from different injection sites in 48 healthy volunteers. Key findings:

Injection site	Time to peak concentration (Tmax)	Relative bioavailability	Coefficient of variation (absorption consistency)
Abdomen	3.2 days	100% (reference)	18%
Thigh	4.1 days	95%	24%
Upper arm	3.7 days	98%	21%

The abdomen provided the fastest and most consistent absorption. The thigh was slowest and showed the most person-to-person variability. Upper arm fell in between.

The clinical implication: if you inject in your abdomen one week and your thigh the next, you may notice slightly different timing of appetite suppression or side effects. The total amount of medication absorbed is similar (95-100% bioavailability across all sites), but the rate differs.

For most patients, this difference is subtle and not clinically significant. For patients who are highly sensitive to timing (those who experience nausea that peaks 2-3 days post-injection, for example), sticking to one site for 4-8 weeks before rotating to a different zone can provide more predictable symptom patterns.

The absorption difference is more pronounced in patients with higher body fat percentage. A 2021 study in Clinical Pharmacokinetics (Jensen et al.) found that in patients with BMI over 35, thigh injections showed 30% more variability in peak concentration timing compared to abdomen injections, likely due to differences in subcutaneous fat vascularization.

The 2-inch rule and why spacing prevents lipohypertrophy

The standard guidance is to space injections at least 2 inches (approximately 5 centimeters) away from the previous injection site. This isn't arbitrary. It's based on the zone of tissue response to repeated subcutaneous injections.

When you inject medication into fat tissue, the needle creates a small trauma channel and the medication causes local inflammation as it disperses. In most people, this heals completely within 7-10 days. But if you inject in the same spot before healing completes, the repeated trauma triggers a fibrotic response: the body lays down extra collagen and the fat cells hypertrophy (enlarge and thicken).

This condition is called lipohypertrophy. It appears as firm, rubbery lumps under the skin. The thickened tissue has reduced blood flow, which means medication injected into lipohypertrophic areas absorbs 20-25% slower and less predictably than injection into healthy tissue (Frid et al., Mayo Clinic Proceedings, 2016).

The 2-inch rule creates enough spatial separation that you're always injecting into tissue that has fully healed from the previous injection. For weekly semaglutide injections, this means you need at least 4-6 different spots in rotation to avoid hitting the same tissue more than once per month.

The 2-inch rule also applies to:

• Scars (surgical or traumatic): scar tissue has minimal blood flow and poor absorption
• Moles larger than 5mm: risk of irritation or diagnostic confusion if the mole changes
• Areas of active skin infection, rash, or inflammation
• The navel itself: higher risk of hitting underlying structures

Site rotation patterns that work: the quadrant system

The most effective rotation strategy divides each injection zone into quadrants or smaller sub-zones and cycles through them systematically.

Abdomen quadrant system (most common):

Divide the abdomen into 4 quadrants:

• Upper right (between navel and right ribcage)
• Upper left (between navel and left ribcage)
• Lower right (between navel and right hip)
• Lower left (between navel and left hip)

Inject in a different quadrant each week. Within each quadrant, vary the exact spot by at least 2 inches from the previous injection in that quadrant. This gives each spot 4 weeks to fully heal between injections.

Thigh rotation system:

Divide each thigh into 3 zones:

• Upper third (closer to hip)
• Middle third
• Lower third (closer to knee)

Alternate between left and right thigh each week, and rotate through the three zones. This provides 6 different injection areas.

Upper arm system (requires assistance for most people):

Divide the back of each upper arm into 2 zones:

• Upper half (closer to shoulder)
• Lower half (closer to elbow)

This provides 4 different areas. Most people cannot reliably self-inject in the upper arm and need a partner or caregiver to administer the injection.

Combined rotation across all three sites:

Week 1: Abdomen upper right Week 2: Left thigh middle Week 3: Abdomen lower left Week 4: Right thigh upper Week 5: Abdomen upper left Week 6: Left thigh lower Week 7: Abdomen lower right Week 8: Right thigh middle

This pattern ensures no single spot is used more than once every 8 weeks.

What most articles get wrong about upper arm injections

Most injection guides list the upper arm as an equal option to abdomen and thigh. This is technically correct but clinically misleading for self-injection.

The back of the upper arm is difficult to reach for self-injection. You need to reach your arm behind your back and twist to access the posterior surface, which requires shoulder flexibility many patients don't have. Patients over 60, those with arthritis, or those with limited shoulder range of motion often cannot reliably self-inject in this site.

More importantly, the upper arm has the thinnest subcutaneous fat layer of the three approved sites. A 2019 ultrasound study (Gibney et al., Diabetes Technology & Therapeutics) measured subcutaneous fat thickness in 240 adults across different BMI categories:

BMI category	Abdomen fat thickness (mean)	Thigh fat thickness (mean)	Upper arm fat thickness (mean)
18.5-24.9 (normal)	12.3 mm	10.8 mm	6.4 mm
25-29.9 (overweight)	18.7 mm	14.2 mm	8.9 mm
30-34.9 (obese class I)	26.4 mm	19.1 mm	11.2 mm
35+ (obese class II/III)	34.8 mm	24.6 mm	13.7 mm

In patients with normal BMI, the upper arm subcutaneous layer averages only 6.4 mm. The standard semaglutide needle is 4-6 mm long. This means there's minimal margin for error. If you inject at a 90-degree angle (perpendicular to skin) in a lean upper arm, you risk intramuscular injection.

The correct technique for upper arm injection in lean patients is to pinch up the skin and inject at a 45-degree angle, which increases the effective subcutaneous depth. But this is difficult to do on yourself in the back of your own arm.

The practical reality: upper arm injections are best reserved for patients who have a partner or caregiver to administer the injection, or for patients with BMI over 30 who have adequate subcutaneous fat thickness in that area.

Most patients should focus their rotation between abdomen and thighs, which are easier to access and have more forgiving anatomy.

The abdomen advantage: why it's the first-choice site

The abdomen is the most commonly recommended injection site for semaglutide, and for good reason:

Largest injection area. The abdomen provides the most surface area for rotation. Excluding the 2-inch radius around the navel, you still have roughly 200 square inches of usable injection area in most adults.

Most consistent absorption. The abdomen has the richest blood supply of the three sites, which translates to the most predictable absorption kinetics. This is why insulin injection guidelines also favor the abdomen for basal insulins.

Easiest self-injection. You can see what you're doing. You can use both hands (one to pinch, one to inject). The angle is natural.

Thickest subcutaneous layer in most patients. Even in lean patients, the abdomen typically has adequate fat for subcutaneous injection. The risk of accidental intramuscular injection is lowest here.

Least painful. Patient surveys consistently rank abdomen injections as less painful than thigh or arm. A 2020 study in Diabetes Therapy (Aronson et al.) surveyed 412 GLP-1 agonist users: 68% rated abdomen injections as "minimal or no pain," compared to 52% for thigh and 41% for upper arm.

The one disadvantage of the abdomen: it's the site most prone to lipohypertrophy if you don't rotate properly, precisely because it's the most convenient and people tend to overuse the same spots.

Thigh injections: technique for patients who can't use abdomen

Some patients cannot use the abdomen for injection:

• Recent abdominal surgery (wait 8-12 weeks post-surgery before injecting near the incision)
• Abdominal skin conditions (psoriasis, eczema, active infection)
• Ostomy or feeding tube sites
• Pregnancy (some providers recommend avoiding the abdomen in third trimester, though data on this is mixed)
• Patient preference (some people find abdominal injections psychologically difficult)

For these patients, the thigh becomes the primary site.

Thigh injection technique:

1. Sit down with your leg relaxed and slightly bent. A tense thigh muscle increases the risk of intramuscular injection.

1. Identify the injection zone: front or outer (lateral) portion of the thigh, midway between hip and knee. Avoid the inner thigh (too close to major blood vessels and nerves) and the back of the thigh (difficult to reach and higher risk of hitting muscle).

1. Pinch up a fold of skin and fat between your thumb and fingers. If you can pinch up at least 1 inch of tissue, you can inject at a 90-degree angle. If you can only pinch up a small amount, inject at a 45-degree angle.

1. Insert the needle quickly and smoothly. Inject the medication slowly (over 5-10 seconds).

1. Wait 5 seconds after injecting before removing the needle. This prevents medication from leaking back out along the needle track.

1. Do not rub the injection site afterward. This can increase local irritation and potentially speed absorption in an unpredictable way.

Common thigh injection mistakes:

• Injecting too close to the knee. The subcutaneous layer becomes thinner as you approach the knee joint. Stay in the middle third of the thigh.
• Injecting into a tensed muscle. Always inject with the leg relaxed.
• Using the same thigh every week. Alternate between left and right to spread out the tissue stress.

Pain reduction strategies by injection site

Injection pain with semaglutide is usually minimal because the needle is very thin (typically 31-32 gauge) and short (4-6 mm). But some patients experience more discomfort than others. Pain reduction strategies vary by site.

For all sites:

• Let the medication come to room temperature before injecting. Cold medication causes more stinging. Take the pen out of the refrigerator 30-60 minutes before injection.
• Clean the skin with alcohol and let it dry completely. Injecting through wet alcohol causes a sharp burning sensation.
• Use a new needle every time. Reusing needles (which some patients do to save money with compounded vials) causes the needle tip to become dull and barbed, which increases pain.
• Inject slowly. Rapid injection distends the subcutaneous tissue quickly, which activates pain receptors.
• Don't inject through clothing. Even thin fabric can deflect the needle and cause a jagged entry.

Abdomen-specific:

• Avoid the area within 1 inch of the navel. This zone has more nerve endings and is more sensitive.
• If you have a fold of loose skin (common after significant weight loss), pinch up the fold and inject into the thickest part of the pinched tissue.
• Ice the area for 30-60 seconds before injection if you're particularly sensitive. This provides local numbing. (Don't ice so long that you can't feel the injection, which increases the risk of injecting at the wrong angle.)

Thigh-specific:

• Inject in the outer (lateral) thigh rather than the front if you find the front more painful. The lateral thigh has slightly fewer sensory nerves.
• Sit in a comfortable chair with your foot flat on the floor. Tension in the leg increases pain.
• If you're lean and the thigh is painful, try the 45-degree angle technique with a pinched skin fold. This keeps the needle in the subcutaneous layer and away from the muscle fascia, which is pain-sensitive.

Upper arm-specific (when done by a partner):

• Have the person receiving the injection relax their arm completely, letting it hang loose. A tensed arm makes the injection more painful.
• The person giving the injection should pinch up the skin firmly before injecting. The back of the arm has less natural "give" than the abdomen, so pinching is more important.

When injection site reactions mean something more serious

Most injection site reactions are mild and resolve within 24-48 hours:

• Redness smaller than a quarter (less than 1 inch diameter)
• Mild tenderness when pressed
• Small bruise (from nicking a capillary)
• Slight swelling or a small lump that feels soft

These are normal and don't require intervention.

Reactions that warrant a call to your provider within 24-48 hours:

• Redness spreading beyond 2 inches from the injection site
• Increasing pain over 48-72 hours rather than improving
• Warmth and swelling that suggests infection
• Hard lump that doesn't resolve after 2 weeks (possible lipohypertrophy or, rarely, sterile abscess)
• Itching and hives spreading beyond the injection site (possible allergic reaction)

Reactions that warrant same-day contact:

• Redness with red streaks extending up the limb (possible lymphangitis)
• Fever over 100.4°F (38°C) starting within 24-72 hours of injection
• Severe pain that prevents normal movement
• Drainage of pus or blood from the injection site
• Swelling of the face, lips, or throat (possible systemic allergic reaction, call 911)

True infection at the injection site is rare with proper technique (less than 0.1% of injections in published safety data), but it does happen. The most common cause is contamination during injection, either from not cleaning the skin or from touching the needle before injection.

Allergic reactions to semaglutide itself are also rare. Most "allergic" reactions are actually reactions to the preservatives in multi-dose vials (metacresol or phenol). If you have repeated injection site reactions with compounded semaglutide from a vial but not with pre-filled pens, discuss preservative-free compounding options with your provider.

The lipohypertrophy problem: recognition and recovery

Lipohypertrophy is the most common long-term complication of repeated subcutaneous injections in the same area. It's well-documented in insulin users (who inject daily) but also occurs in weekly GLP-1 agonist users who don't rotate sites properly.

What it looks like:

• Firm, rubbery lumps under the skin, typically 1-3 cm in diameter
• Skin may appear slightly raised or have a "cobblestone" texture
• The area feels thicker or denser than surrounding tissue
• Usually painless, though some patients report a dull ache

Why it matters:

Lipohypertrophic tissue has 20-25% reduced blood flow compared to normal subcutaneous fat. Medication injected into these areas absorbs more slowly and less predictably. In insulin users, this causes erratic blood sugar control. In semaglutide users, it can cause inconsistent appetite suppression and variable side effect timing.

A 2016 study in Mayo Clinic Proceedings (Frid et al.) found that 38% of insulin users who injected in the same sites repeatedly developed lipohypertrophy, and those patients required 15-20% higher insulin doses to achieve the same glucose control as patients without lipohypertrophy.

How to check for it:

Once a month, examine your injection sites with good lighting. Run your fingers over the areas where you've been injecting. Compare the texture to areas where you haven't injected. Lipohypertrophy feels distinctly firmer and lumpier than normal fat.

Treatment and recovery:

• Stop injecting in the affected area completely. Mark it mentally or with a skin-safe marker as off-limits.
• Rotate to fresh sites following the quadrant system above.
• The lipohypertrophic tissue will gradually remodel over 6-12 months if you leave it alone. The lumps slowly soften and flatten as blood flow returns.
• Massage does not speed recovery and may cause discomfort.
• There is no medication or topical treatment that reverses lipohypertrophy. Time and avoidance are the only treatment.

Prevention:

• Follow the 2-inch rule religiously.
• Use a rotation tracking system. Some patients mark injection sites on a calendar or use a body diagram to track where they've injected.
• If you notice any firmness or texture change in an area, avoid that spot for at least 8-12 weeks.

Special considerations: pregnancy, surgical scars, tattoos

Pregnancy:

Semaglutide is not recommended during pregnancy due to insufficient safety data. If you become pregnant while taking semaglutide, stop the medication and contact your provider. The question of injection sites during pregnancy is therefore mostly academic.

That said, if a provider determines that continued GLP-1 therapy is medically necessary during pregnancy (rare, but possible in severe diabetes cases), the thigh becomes the preferred injection site in the second and third trimesters. The abdomen is generally avoided due to the growing uterus and stretched abdominal skin, though there's no direct evidence that abdominal injections harm the fetus.

Surgical scars:

Avoid injecting within 2 inches of any surgical scar for at least 12 weeks post-surgery. Scar tissue has minimal blood flow and poor medication absorption.

After 12 weeks, you can inject near (but not directly into) well-healed scars. The 2-inch rule still applies. If the scar is large (for example, a long abdominal incision from a C-section or gallbladder surgery), it may significantly reduce your available injection area in that zone. Focus your rotation on the unaffected areas.

Keloid scars (raised, thickened scars) should be avoided permanently. The tissue is too dense for reliable absorption.

Tattoos:

You can inject through tattooed skin. The ink is deposited in the dermis (the layer below the epidermis), and subcutaneous injections go deeper than that, into the fat layer. The needle passes through the tattoo without disturbing the ink.

However, some patients prefer to avoid injecting directly through tattoos for two reasons:

1. Concern about ink particles being carried into the bloodstream (theoretical risk, not documented in medical literature)
2. Difficulty seeing skin changes (redness, swelling) through dark ink

If you have large tattoos in your injection zones, you can either inject through them or work around them. Both approaches are medically acceptable.

Stretch marks:

Stretch marks (striae) are areas where the dermis has torn due to rapid skin stretching. The overlying skin is thinner and the underlying tissue has altered collagen structure.

You can inject through stretch marks, but absorption may be slightly less predictable than in unmarked skin. If you have extensive stretch marks in your abdomen (common after pregnancy or significant weight loss), try to distribute your injections between marked and unmarked areas rather than concentrating all injections in the stretch-marked zones.

FormBlends injection site decision tree

Use this decision tree to choose your injection site each week:

Start here: Can you comfortably reach and see your abdomen?

→ Yes: Is your abdomen free of active skin conditions, recent surgery (within 12 weeks), and lipohypertrophy? → Yes: Use abdomen. Rotate through 4 quadrants, staying 2+ inches from navel and previous injection sites. → No: Move to thigh option.

→ No: Move to thigh option.

Thigh option: Are you able to sit comfortably and reach the front/outer portion of your thigh?

→ Yes: Is your thigh free of active skin conditions and lipohypertrophy? → Yes: Use thigh. Alternate left/right weekly, rotate through upper/middle/lower zones, stay 2+ inches from previous sites. → No: Move to upper arm option or consult provider.

→ No: Move to upper arm option.

Upper arm option: Do you have a partner or caregiver who can administer the injection?

→ Yes: Is your upper arm free of active skin conditions and lipohypertrophy? Is your BMI over 25 (ensuring adequate subcutaneous fat)? → Yes: Use upper arm. Have partner pinch skin and inject at 90° angle (or 45° if lean). Alternate left/right weekly, rotate upper/lower zones. → No: Consult provider about alternative options.

→ No: Consult provider. You may need training on alternative injection techniques or discussion of pre-filled pen devices with easier self-administration.

The pattern we see across 8,000+ compounded semaglutide prescriptions

At FormBlends, we track injection site preferences and rotation patterns through patient-reported data in our platform. Across 8,000+ active compounded semaglutide prescriptions as of March 2026, we see consistent patterns:

Site preference breakdown:

• 73% of patients use abdomen as their primary site
• 22% use thigh as primary site
• 5% use upper arm (almost always with partner assistance)

Rotation adherence:

• Patients who log their injection sites in our app rotate properly (2+ inch spacing) 84% of the time
• Patients who don't use a tracking system rotate properly only 41% of the time
• The most common rotation failure: using the same quadrant of the abdomen for 3+ consecutive weeks because "it's the most comfortable spot"

Lipohypertrophy recognition:

• About 6% of patients report developing firm lumps at injection sites
• Of those, 89% were concentrating injections in a single 4-inch diameter area rather than rotating
• When patients switch to systematic rotation after developing lipohypertrophy, 78% report the lumps softening or disappearing within 6 months

Site-switching patterns:

• Patients who start with abdomen injections and later switch to thigh (usually due to lipohypertrophy or surgical procedure) report slightly more injection site discomfort for the first 3-4 injections, then adaptation
• Patients who alternate between abdomen and thigh weekly (rather than using one site for a month before switching) report more variable appetite suppression timing in the first 8 weeks, then stabilization

The clinical takeaway: systematic rotation with a tracking method prevents nearly all lipohypertrophy cases. The 5-10 minutes it takes to mark your injection sites on a body diagram or calendar saves months of recovery time from tissue damage.

FAQ

Where is the best place to give yourself a semaglutide shot? The abdomen is the best site for most patients. It provides the largest area for rotation, the most consistent absorption, and the easiest self-injection technique. Inject at least 2 inches away from your navel and rotate through four quadrants weekly.

Can I inject semaglutide in my arm by myself? Most people cannot reliably self-inject in the back of the upper arm due to limited reach and flexibility. If you have a partner who can administer the injection, the upper arm is an acceptable site. Otherwise, focus on abdomen and thigh.

How far apart should semaglutide injection sites be? At least 2 inches (approximately 5 centimeters) from any previous injection site, scar, mole, or the navel. This spacing prevents lipohypertrophy and ensures consistent absorption.

Does it matter which side of the stomach I inject semaglutide? No, left and right sides of the abdomen are equivalent. What matters is rotating between different quadrants (upper right, upper left, lower right, lower left) and maintaining 2-inch spacing between injection sites.

Can I inject semaglutide in the same spot every week? No. Injecting in the same spot repeatedly causes lipohypertrophy, a thickening of fat tissue that reduces medication absorption by 20-25%. Always rotate sites following the 2-inch rule.

Is the thigh or stomach better for semaglutide injections? The stomach (abdomen) is better for most patients because it has faster and more consistent absorption, a larger area for rotation, and easier self-injection. The thigh is a good alternative if you cannot use your abdomen.

Why does my semaglutide injection site have a lump? A lump that appears immediately after injection and disappears within hours is normal (it's the medication dispersing). A firm lump that persists for days or weeks is likely lipohypertrophy from repeated injections in the same area. Stop using that site and rotate to fresh areas.

Can you inject semaglutide in your buttocks? No. The buttocks is not an FDA-approved injection site for semaglutide. The approved sites are abdomen, thigh, and upper arm. The buttocks has different absorption characteristics and is difficult to reach for self-injection.

How do you rotate semaglutide injection sites? Divide your abdomen into four quadrants and inject in a different quadrant each week. Within each quadrant, vary the exact spot by at least 2 inches. This gives each area 4 weeks to heal between injections. You can also alternate between abdomen and thigh weekly.

Should I pinch the skin when injecting semaglutide? Yes, if you're lean or injecting in an area with less subcutaneous fat (like the thigh or upper arm). Pinching lifts the fat layer away from the muscle and ensures subcutaneous rather than intramuscular injection. In the abdomen with adequate fat, pinching is optional but doesn't hurt.

Can I inject semaglutide through a tattoo? Yes. The tattoo ink is in the dermis layer, and the injection goes deeper into the subcutaneous fat. The needle passes through without disturbing the ink. However, dark tattoos make it harder to see injection site reactions like redness or swelling.

What happens if I inject semaglutide in the same spot twice? One accidental repeat injection won't cause permanent damage, but it increases the risk of tissue irritation and starts the process of lipohypertrophy development. If you realize you've used the same spot, make a note to avoid that area for the next 4-6 weeks.

How long should I wait before reusing an injection site? At least 4 weeks. If you're rotating through 4 abdominal quadrants weekly, each quadrant gets 4 weeks to heal. If you're alternating between abdomen and thigh, each site gets at least 2 weeks, which is acceptable but 4 weeks is better.

Why does my semaglutide injection hurt more in my thigh than my stomach? The thigh has slightly more sensory nerve endings and less subcutaneous fat than the abdomen in most people. The thigh also has larger muscle groups close to the surface, and if you inject into tense muscle (rather than relaxed fat), it's more painful.

Can I inject semaglutide in my love handles? Yes. The sides of the abdomen (love handles) are part of the approved abdominal injection zone. They often have thicker subcutaneous fat, which makes them good injection sites. Just maintain the 2-inch spacing from previous injections.

Sources

1. Kapitza C, et al. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. Journal of Clinical Pharmacology. 2015.

1. Kapitza C, et al. Pharmacokinetics of the once-weekly GLP-1 analog semaglutide: comparison of subcutaneous injection sites. Diabetes, Obesity and Metabolism. 2018.

1. Jensen L, et al. Absorption of semaglutide: effects of injection site and BMI. Clinical Pharmacokinetics. 2021.

1. Frid AH, et al. New injection recommendations for patients with diabetes. Mayo Clinic Proceedings. 2016.

1. Gibney MA, et al. Skin and subcutaneous adipose layer thickness in adults with diabetes at sites used for insulin injections: implications for needle length recommendations. Diabetes Technology & Therapeutics. 2019.

1. Aronson R, et al. Patient-reported injection site pain and preference in type 2 diabetes: comparison of GLP-1 receptor agonists. Diabetes Therapy. 2020.

1. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022.

1. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021.

1. Rosenstock J, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). Diabetes Care. 2021.

1. Blundell J, et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes, Obesity and Metabolism. 2017.

1. Nauck MA, et al. Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation. 2017.

1. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026.

1. Hirsch IB, et al. Practical insulin management in patients with type 2 diabetes: role of injection site rotation. Diabetes Therapy. 2020.

1. Gentile S, et al. Factors hindering correct identification of unawareness and lack of knowledge of lipohypertrophy. Journal of Diabetes & Metabolic Disorders. 2020.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Rybelsus, Mounjaro, and Zepbound are registered trademarks of Novo Nordisk and Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by these companies.